Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 DDI Study with Midazolam and Repaglinide
NCT06290050Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zasocitinib in psoriasis, sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity and 1 more. Started Mar 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06290050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290050.